MoonLake Immunotherapeutics - Class A
News
MoonLake Immunotherapeutics: A Strong Buy on Breakthrough Treatment and Market Growth Potential
TipRanks Financial Blog Julian Harrison, an analyst from BTIG, maintained the Buy rating on MoonLake Immunotherapeutics (MLTX - Research Report). The associated price targ...\n more…
Buy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Hidradenitis Suppurativa Treatment Prospects
TipRanks Financial Blog MoonLake Immunotherapeutics (MLTX - Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selv...\n more…
MoonLake Immunotherapeutics: A Strong Buy on Promising Sonelokimab Trials and Market Potential
TipRanks Financial Blog Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on MoonLake Immunotherapeutics (MLTX - Research Report), retaining the price targe...\n more…
Buy Rating on MoonLake Immunotherapeutics: Promising SLK Clinical Programs and Market Growth Potential
TipRanks Financial Blog Analyst Serge Belanger of Needham maintained a Buy rating on MoonLake Immunotherapeutics (MLTX - Research Report), retaining the price target of $6...\n more…
TD Asset Management Inc Buys 5,140 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)
Ticker Report TD Asset Management Inc boosted its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 2.5% during the second quarter, Holdings Channel.com reports. The fund owned...\n more…
Zurcher Kantonalbank Zurich Cantonalbank Reduces Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)
Ticker Report Zurcher Kantonalbank Zurich Cantonalbank trimmed its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 31.7% in the 2nd quarter, according to the company in its most recent filing...\n more…